Pharmaceutical - Markets & Marketing, Oncology

Filter

Popular Filters

1 to 25 of 153 results

Strong growth forecast for glioblastoma multiforme therapeutics in Asia-Pacific

Strong growth forecast for glioblastoma multiforme therapeutics in Asia-Pacific

26-08-2014

The glioblastoma multiforme therapeutics market in the four Asia-Pacific markets of Australia, China,…

Asia-PacificAustraliaAvastinCelldex TherapeuticsChinaCotaraIndiaJapanMarkets & MarketingOncologyPeregrine PharmaceuticalsPharmaceuticalrindopepimutRoche

Turkish man pleads guilty to importing illegal cancer drugs into USA

Turkish man pleads guilty to importing illegal cancer drugs into USA

17-08-2014

Sabahaddin Akman, owner of the Istanbul, Turkey, firm Ozay Pharmaceuticals, has pleaded guilty to charges…

AvastinLegalMarkets & MarketingOncologyOzay PharmaceuticalsPharmaceuticalRituxanSabahaddin AkmanTurkeyUSA

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

11-08-2014

The treatment landscape of gastrointestinal stromal tumors (GIST) will not change dramatically through…

BayerGleevecGlivecMarkets & MarketingNovartisOncologyPfizerPharmaceuticalStivargaSutent

Sanofi partners with Emcure for oncology portfolio in India

Sanofi partners with Emcure for oncology portfolio in India

06-08-2014

French pharma major Sanofi’s Indian subsidiary said today that it has entered into a marketing and…

Emcure PharmaceuticalsFasturtecFludaraIndiaJevtanaMarkets & MarketingOncologyPharmaceuticalSanofiTaxotere

US and European orphan status for AbbVie’s glioblastoma candidate

US and European orphan status for AbbVie’s glioblastoma candidate

04-08-2014

Both the European Medicines Agency and the US Food and Drug Administration have granted orphan drug designation…

AbbVieABT-414Brain tumorEuropeGlioblastoma multiformeMarkets & MarketingOncologyPharmaceuticalRare diseasesRegulationUS Food and Drug AdministrationUSA

New entrants in chronic lymphocytic leukemia will raise market value to $3.3 billion by 2018

New entrants in chronic lymphocytic leukemia will raise market value to $3.3 billion by 2018

02-07-2014

The introduction of several new drugs will accelerate growth in the chronic lymphocytic leukemia treatment…

EuropeidelalisibImbruvicaMarkets & MarketingOncologyPharmaceuticalUSA

Cancer immunotherapy market set to grow to nearly $9 billion across major markets in 2022

Cancer immunotherapy market set to grow to nearly $9 billion across major markets in 2022

01-07-2014

The cancer immunotherapy market will experience considerable growth through 2022, increasing from $1.1…

AstraZenecaBristol-Myers SquibbEuropeJapanMarkets & MarketingMED14736Merck & ConivolumabOncologypembrolizumabPharmaceuticalResearchRocheUSAYervoy

DCVax-L vaccine launch to boost glioblastoma market to $626 million by 2020

DCVax-L vaccine launch to boost glioblastoma market to $626 million by 2020

12-06-2014

The glioblastoma multiforme (GBM) treatment market is forecast to expand rapidly from a value of $301…

Celldex TherapeuticsCotaraDCVaxMarkets & MarketingNorthwest BiotherapeuticsOncologyPeregrine PharmaceuticalsPharmaceuticalResearchrindopepimut

China’s FDA warns of on-line sales of fake cancer drug

China’s FDA warns of on-line sales of fake cancer drug

12-06-2014

China's drug administration on Wednesday warned consumers not to purchase illegally imported cancer drugs…

ChinaMarkets & MarketingOncologyPharmaceuticalRegulation

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

Modest growth expected for pancreatic cancer therapy market

30-04-2014

Fueled by the increasing global prevalence of pancreatic cancer (PC), coupled with the approval of at…

Markets & MarketingMerrimack PharmaceuticalsMM-398OncologyPharmaceuticalResearchTH-302Threshold Pharmaceuticals

US oncologists prescribing of Boehringer's Gilotrif for NSCLC

25-04-2014

Just six months post-launch in the USA, 49% of surveyed US medical oncologists have prescribed German…

Boehringer IngelheimGilotrifMarkets & MarketingOncologyPharmaceuticalUSA

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters

17-04-2014

The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

09-04-2014

Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

Pharmaceutical companies to benefit from new blood cancer drugs

04-04-2014

Blood cancer drugs represent a growth opportunity for the pharmaceutical industry over the next few years,…

AmgenCelgeneGilead SciencesJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRoche

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

28-03-2014

Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast…

AfinitorbuparlisibGlaxoSmithKlineHerceptinMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheTykerb

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

18-03-2014

The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region -…

Asia-PacificAustraliaChinaIndiaJapanMarkets & MarketingOncologyPharmaceutical

Roche’s breast cancer drug Kadcyla debuts in UK

Roche’s breast cancer drug Kadcyla debuts in UK

13-02-2014

Swiss drug major Roche’s Kadcyla (ado-trastuzumab emtansine or T-DM1) is now available for UK patients…

KadcylaMarkets & MarketingNorthern EuropeOncologyPharmaceuticalRocheUK

Bladder cancer market to witness moderate growth by 2017, despite anticipated launch of EOoquin

Bladder cancer market to witness moderate growth by 2017, despite anticipated launch of EOoquin

22-01-2014

The bladder cancer therapeutics market in the six major countries is forecast to climb from $239.3 million…

EOquinEuropeMarkets & MarketingOncologyPharmaceuticalSpectrum PharmaceuticalsUSA

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

6% annual growth forecast for NSCLC market in major Latin America countries

6% annual growth forecast for NSCLC market in major Latin America countries

12-12-2013

From 2013 to 2018, the non-small-cell lung cancer (NSCLC) market in Argentina, Brazil and Mexico will…

ArgentinaBrazilMarkets & MarketingOncologyPharmaceuticalSouth America

1 to 25 of 153 results

Back to top